Special Issue "Models of Experimental Liver Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 August 2019
Prof. Dr. Diego F. Calvisi
Professor of Experimental Tumor Pathology, Institut für Pathologie, Universitätsklinikum, Regensburg, Germany;
Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy
Website | E-Mail
Interests: liver cancer; hepatocellular carcinoma; cholangiocarcinoma; hepatoblastoma; mouse models; cancer genetics and epigenetics; signal transduction; cancer metabolism; precision medicine
Primary liver cancer (PLC) ranks among the most frequent and deadly tumors worldwide, with a steadily increasing incidence and few therapeutic options. PLC consists of two main histological subtypes in the adult, namely hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), and of hepatoblastoma (HBL) in children. Due to the paucity of symptoms and the absence of reliable biomarkers for early detection, PLC is most often detected in advanced stages, when curative therapies are not applicable and loco-regional approaches are of limited patient benefit. To overcome this gloomy scenario, a number of in vitro and in vivo experimental models have been generated and are currently under development. These models have been highly useful to understand the genetic predisposition to liver cancer, the malignant properties of chemicals and environmental factors, the histopathological alterations occurring along liver tumor development and progression, the identification of diagnostic and prognostic markers, and the oncogenic potential of aberrantly activated or inactivated signaling pathways. Recent and future models will be extremely helpful to address pivotal unsolved questions, such as intratumor heterogeneity, functional interplay between PLC cells and the tumor microenvironment, the role of signaling pathways crosstalk, metabolic addiction, and response/resistance to conventional and tailored therapies.
Given the importance of PLC in the field of medicine and research, the journal Cancers is launching this Special Issue. Our aim is to bring together a collection of original research articles and incisive reviews providing fertile ground for insightful discussions and new ideas for the understanding and the treatment of this pernicious disease.
Prof. Dr. Diego F. Calvisi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.